JP2017119633A - Agent for promoting growth and/or suppressing decrease in bifidobacterium bacteria and/or lactic acid bacteria - Google Patents
Agent for promoting growth and/or suppressing decrease in bifidobacterium bacteria and/or lactic acid bacteria Download PDFInfo
- Publication number
- JP2017119633A JP2017119633A JP2015255967A JP2015255967A JP2017119633A JP 2017119633 A JP2017119633 A JP 2017119633A JP 2015255967 A JP2015255967 A JP 2015255967A JP 2015255967 A JP2015255967 A JP 2015255967A JP 2017119633 A JP2017119633 A JP 2017119633A
- Authority
- JP
- Japan
- Prior art keywords
- bacteria
- milk
- lactic acid
- growth
- bifidobacterium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims abstract description 132
- 241000894006 Bacteria Species 0.000 title claims abstract description 118
- 241000186000 Bifidobacterium Species 0.000 title claims abstract description 94
- 239000004310 lactic acid Substances 0.000 title claims abstract description 66
- 235000014655 lactic acid Nutrition 0.000 title claims abstract description 66
- 230000001737 promoting effect Effects 0.000 title claims abstract description 43
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 29
- 239000000203 mixture Substances 0.000 claims abstract description 25
- 102000004169 proteins and genes Human genes 0.000 claims description 43
- 235000018102 proteins Nutrition 0.000 claims description 42
- 108090000623 proteins and genes Proteins 0.000 claims description 42
- 150000001720 carbohydrates Chemical class 0.000 claims description 28
- 239000003112 inhibitor Substances 0.000 claims description 24
- 235000014633 carbohydrates Nutrition 0.000 claims description 21
- 229920001542 oligosaccharide Polymers 0.000 claims description 12
- 150000002482 oligosaccharides Chemical class 0.000 claims description 12
- 150000002016 disaccharides Chemical class 0.000 claims description 9
- 150000002772 monosaccharides Chemical class 0.000 claims description 9
- 230000035755 proliferation Effects 0.000 claims description 9
- 230000009467 reduction Effects 0.000 claims description 9
- 102000014171 Milk Proteins Human genes 0.000 claims description 8
- 108010011756 Milk Proteins Proteins 0.000 claims description 8
- 235000021239 milk protein Nutrition 0.000 claims description 8
- 230000001629 suppression Effects 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 5
- 206010010774 Constipation Diseases 0.000 claims description 4
- 206010012735 Diarrhoea Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 244000005709 gut microbiome Species 0.000 claims description 3
- 230000007365 immunoregulation Effects 0.000 claims 1
- 238000005516 engineering process Methods 0.000 abstract description 54
- 230000004083 survival effect Effects 0.000 abstract description 24
- 239000004615 ingredient Substances 0.000 abstract description 11
- 241000244268 Peucedanum japonicum Species 0.000 abstract description 4
- 235000013336 milk Nutrition 0.000 description 47
- 239000008267 milk Substances 0.000 description 47
- 210000004080 milk Anatomy 0.000 description 47
- 235000013305 food Nutrition 0.000 description 41
- 239000000047 product Substances 0.000 description 32
- 239000000843 powder Substances 0.000 description 31
- 230000000694 effects Effects 0.000 description 23
- 108010046377 Whey Proteins Proteins 0.000 description 21
- 230000003247 decreasing effect Effects 0.000 description 21
- 235000020183 skimmed milk Nutrition 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- 102000007544 Whey Proteins Human genes 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 20
- 235000000346 sugar Nutrition 0.000 description 16
- 238000012258 culturing Methods 0.000 description 15
- 241001608472 Bifidobacterium longum Species 0.000 description 13
- 108010076119 Caseins Proteins 0.000 description 13
- 102000011632 Caseins Human genes 0.000 description 13
- 229940009291 bifidobacterium longum Drugs 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 13
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 12
- 235000021240 caseins Nutrition 0.000 description 12
- 230000036541 health Effects 0.000 description 12
- 239000005862 Whey Substances 0.000 description 11
- 235000013361 beverage Nutrition 0.000 description 11
- 239000005018 casein Substances 0.000 description 11
- 235000009508 confectionery Nutrition 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 235000013322 soy milk Nutrition 0.000 description 10
- 235000020679 tap water Nutrition 0.000 description 10
- 239000008399 tap water Substances 0.000 description 10
- 235000021119 whey protein Nutrition 0.000 description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 8
- 235000021581 juice product Nutrition 0.000 description 8
- 239000008101 lactose Substances 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 240000005979 Hordeum vulgare Species 0.000 description 7
- 235000007340 Hordeum vulgare Nutrition 0.000 description 7
- 241000186605 Lactobacillus paracasei Species 0.000 description 7
- 235000008476 powdered milk Nutrition 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000004278 EU approved seasoning Substances 0.000 description 6
- 241000186606 Lactobacillus gasseri Species 0.000 description 6
- -1 cinderose Chemical class 0.000 description 6
- 235000013365 dairy product Nutrition 0.000 description 6
- 235000011194 food seasoning agent Nutrition 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 235000020185 raw untreated milk Nutrition 0.000 description 6
- 229920001353 Dextrin Polymers 0.000 description 5
- 239000004375 Dextrin Substances 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 235000019425 dextrin Nutrition 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003925 fat Substances 0.000 description 5
- 235000013861 fat-free Nutrition 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 235000013611 frozen food Nutrition 0.000 description 5
- 235000020251 goat milk Nutrition 0.000 description 5
- 244000144972 livestock Species 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000007952 growth promoter Substances 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241000186012 Bifidobacterium breve Species 0.000 description 3
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 235000020194 almond milk Nutrition 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229940004120 bifidobacterium infantis Drugs 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 235000013351 cheese Nutrition 0.000 description 3
- 235000020197 coconut milk Nutrition 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 235000020247 cow milk Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 235000015203 fruit juice Nutrition 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 235000015243 ice cream Nutrition 0.000 description 3
- 230000003832 immune regulation Effects 0.000 description 3
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 3
- 229960000511 lactulose Drugs 0.000 description 3
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000019426 modified starch Nutrition 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 235000013616 tea Nutrition 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 240000001929 Lactobacillus brevis Species 0.000 description 2
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 description 2
- 241000194034 Lactococcus lactis subsp. cremoris Species 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 244000294411 Mirabilis expansa Species 0.000 description 2
- 235000015429 Mirabilis expansa Nutrition 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 235000014962 Streptococcus cremoris Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 235000015155 buttermilk Nutrition 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229940071162 caseinate Drugs 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 150000002337 glycosamines Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- 229940017800 lactobacillus casei Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000013536 miso Nutrition 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 235000021110 pickles Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 235000013580 sausages Nutrition 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 241001134770 Bifidobacterium animalis Species 0.000 description 1
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 101000798100 Bos taurus Lactotransferrin Proteins 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000012905 Brassica oleracea var viridis Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 244000172809 Leuconostoc cremoris Species 0.000 description 1
- 235000017632 Leuconostoc cremoris Nutrition 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000218180 Papaveraceae Species 0.000 description 1
- 241000192001 Pediococcus Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 241000209056 Secale Species 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 241000194024 Streptococcus salivarius Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000500334 Tetragenococcus Species 0.000 description 1
- 241000500332 Tetragenococcus halophilus Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001278 adipic acid derivatives Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229940118852 bifidobacterium animalis Drugs 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 229940009289 bifidobacterium lactis Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229940036811 bone meal Drugs 0.000 description 1
- 239000002374 bone meal Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229940072440 bovine lactoferrin Drugs 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000012813 breadcrumbs Nutrition 0.000 description 1
- 235000020246 buffalo milk Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 108010033929 calcium caseinate Proteins 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013574 canned fruits Nutrition 0.000 description 1
- 235000014613 canned/preserved soup Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 229940021722 caseins Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000021557 concentrated beverage Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 235000019543 dairy drink Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000021185 dessert Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- OENDOEZBSDLANK-UHFFFAOYSA-N dimagnesiomagnesium Chemical compound [Mg][Mg][Mg] OENDOEZBSDLANK-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 235000020252 horse milk Nutrition 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 235000008446 instant noodles Nutrition 0.000 description 1
- 235000014109 instant soup Nutrition 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 229940025902 konjac mannan Drugs 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 150000003272 mannan oligosaccharides Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000016046 other dairy product Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000002957 persistent organic pollutant Substances 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000015108 pies Nutrition 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 239000001967 plate count agar Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 235000020254 sheep milk Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 125000005624 silicic acid group Chemical class 0.000 description 1
- NGHMEZWZOZEZOH-UHFFFAOYSA-N silicic acid;hydrate Chemical compound O.O[Si](O)(O)O NGHMEZWZOZEZOH-UHFFFAOYSA-N 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 235000020138 yakult Nutrition 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本技術はビフィドバクテリウム属細菌(以下、単に「ビフィズス菌」とも称する)および/または乳酸菌の増殖を促進または減少を抑制するために用いられる増殖促進および/または減少抑制剤、並びに増殖促進および/または減少抑制方法に関する。また本技術は、当該増殖促進および/または減少抑制剤とともにビフィズス菌および/または乳酸菌を含有する経口組成物に関する。 The present technology relates to a growth promoting and / or reducing inhibitor used for promoting or suppressing the growth of Bifidobacterium (hereinafter also simply referred to as “Bifidobacterium”) and / or lactic acid bacteria, and the growth promoting and The present invention relates to a method for suppressing decrease. The present technology also relates to an oral composition containing bifidobacteria and / or lactic acid bacteria together with the growth promoting and / or decrease inhibitor.
ビフィズス菌は、哺乳類(ヒトを含む)の腸管内常在菌であり、それ自体に病原性はなく、むしろ乳酸や酢酸の産生や栄養要求性等の点から病原性腸内細菌に拮抗し、これらの菌の腸管内での増殖を阻害する作用があることが知られている。 Bifidobacteria are resident bacteria in the gut of mammals (including humans) and are not pathogenic in their own right. Rather, they antagonize pathogenic enterobacteria in terms of lactic acid and acetic acid production and auxotrophy, It is known to have an action of inhibiting the growth of these bacteria in the intestinal tract.
一般に、乳児の大腸内の腸内フローラ(腸内菌叢)はビフィズス菌が優勢であるが、その菌叢は加齢とともに変動する。具体的には、青年期から壮年期にかけてビフィズス菌は減少し、クロストリジウム属細菌や大腸菌などの腐敗菌が顕著に増加する。その結果、腸内環境は悪化し、宿主(人)の健康に悪影響がもたらされる。このため、人が年をとっても長く健康を維持するためには、腸内フローラをビフィズス菌等の有用菌が常に優勢な状態に維持しておくことが極めて重要である。 In general, bifidobacteria are dominant in the intestinal flora (intestinal flora) in the large intestine of infants, but the flora varies with aging. Specifically, bifidobacteria decrease from adolescence to middle age, and spoilage bacteria such as Clostridium bacteria and Escherichia coli increase markedly. As a result, the intestinal environment deteriorates and adversely affects the health of the host (person). For this reason, in order to maintain health for a long time as a person ages, it is extremely important to keep the intestinal flora in a state in which useful bacteria such as bifidobacteria are always dominant.
一方、乳酸菌は、通常、ヨーグルト等の乳製品や漬け物等の発酵食品に含まれており、これを哺乳類(ヒトを含む)が食することでその腸内に入り、腸内細菌のバランスを正常化したり、整腸作用を発揮する。また最近では、乳酸菌には、花粉症やアトピー性皮膚炎、ぜんそくなどのアレルギー疾患を抑える働きがあること、免疫メカニズムを調節することによりインフルエンザ感染予防があること、血中の善玉コレステロールの低下を抑え、中性脂肪の値を低下させる効果が期待できることも示されている。 On the other hand, lactic acid bacteria are usually contained in dairy products such as yogurt and fermented foods such as pickles, and when they are eaten by mammals (including humans), they enter the intestine and normal balance of enteric bacteria is normal. Or exert an intestinal regulating action. Recently, lactic acid bacteria have the ability to suppress allergic diseases such as hay fever, atopic dermatitis, asthma, prevent influenza infection by regulating immune mechanisms, and reduce good cholesterol in the blood. It has also been shown that an effect of suppressing and lowering the value of neutral fat can be expected.
こうしたことから、従来よりビフィズス菌や乳酸菌の増殖を促進する物質(以下、単に「増殖促進剤」とも称する)が求められており、数多くの増殖促進剤が開発され提案されている。 For these reasons, substances that promote the growth of bifidobacteria and lactic acid bacteria (hereinafter also simply referred to as “growth promoters”) have been sought, and many growth promoters have been developed and proposed.
現在、ビフィズス菌の増殖促進剤として知られているものとして、例えばフラクトオリゴ糖、ガラクトオリゴ糖、キシロオリゴ糖、イソマルトオリゴ糖、及び大豆オリゴ糖などのオリゴ糖;N−アセチルグルコサミン、ラクチュロース、ラフィノース、セアンデロース、シクロデキストリン、及びコンニャクマンナン等の糖質(以上、特許文献1〜4、非特許文献1〜3);豆乳及び豆乳抽出物(特許文献5〜6);茶抽出物(特許文献7);リン酸カルシウム(特許文献8);牛ラクトフェリン、牛アポラクトフィリン及び牛ラクトフィリン鉄(特許文献9)などを挙げることができる。 Currently known as Bifidobacteria growth promoters include, for example, oligosaccharides such as fructooligosaccharide, galactooligosaccharide, xylo-oligosaccharide, isomaltoligosaccharide, and soybean oligosaccharide; N-acetylglucosamine, lactulose, raffinose, cinderose, Sugars such as cyclodextrin and konjac mannan (Patent Documents 1 to 4, Non-Patent Documents 1 to 3); Soymilk and Soymilk Extract (Patent Documents 5 to 6); Tea Extract (Patent Document 7); Calcium Phosphate (Patent Document 8); Bovine lactoferrin, bovine apolactophyrin, bovine lactophilin iron (Patent Document 9) and the like can be mentioned.
前述の通り、従来から、ビフィズス菌や乳酸菌の増殖を促進する物質の更なる開発が望まれている。ビフィズス菌や乳酸菌は、その存在環境によって、増殖が促進される場合、菌数に変化がない場合、減少する場合がある。
そこで、本技術では、ビフィズス菌や乳酸菌が増殖したり菌数に変化がない環境下においては増殖を促進させ、生存または生育(増殖)しにくい環境下においては減少を抑制させ得る技術を提供することを主目的とする。
As described above, there has been a demand for further development of substances that promote the growth of bifidobacteria and lactic acid bacteria. Bifidobacteria and lactic acid bacteria may be reduced if their growth is promoted by the environment in which they exist, or if the number of bacteria remains unchanged.
Therefore, the present technology provides a technology that can promote proliferation in an environment where bifidobacteria and lactic acid bacteria grow or have no change in the number of bacteria, and can suppress a decrease in an environment that is difficult to survive or grow (grow). The main purpose.
本発明者らは、前記課題を解決すべく、鋭意検討を重ねた結果、セリ科の多年草植物であるボタンボウフウをビフィズス菌および/または乳酸菌と共存させることでその増殖が有意に促進され菌数が増加すること、つまりボタンボウフウにビフィズス菌および/または乳酸菌の増殖を促進する作用があることを見出した。 As a result of intensive studies to solve the above-mentioned problems, the present inventors have promoted the proliferation significantly by coexisting button-bow fu, which is a perennial plant of the Apiaceae family, with bifidobacteria and / or lactic acid bacteria. In other words, it has been found that button bowfish has an effect of promoting the growth of bifidobacteria and / or lactic acid bacteria.
即ち、本技術では、まず、ボタンボウフウを有効成分とする、ビフィドバクテリウム属細菌および/または乳酸菌の増殖促進および/または減少抑制剤を提供する。
本技術に係る増殖促進および/または減少抑制剤には、さらにタンパク質および糖質からなる群から選択される少なくとも1種を含有させることもできる。
この場合、上記タンパク質としては、乳タンパク質を選択することができる。
また、上記糖質としては、単糖、二糖およびオリゴ糖からなる群から選択される少なくとも1種を選択することができる。
That is, the present technology first provides an agent for promoting and / or reducing the growth of Bifidobacterium bacteria and / or lactic acid bacteria, which comprises button fountain as an active ingredient.
The proliferation promoting and / or decrease suppressing agent according to the present technology may further contain at least one selected from the group consisting of proteins and carbohydrates.
In this case, milk protein can be selected as the protein.
Moreover, as said saccharide | sugar, at least 1 sort (s) selected from the group which consists of a monosaccharide, a disaccharide, and an oligosaccharide can be selected.
本技術では、次に、ボタンボウフウと、
ビフィドバクテリウム属細菌および乳酸菌からなる群から選択される少なくとも1種の細菌と、を含む経口組成物を提供する。
本技術に係る経口組成物には、さらにタンパク質および糖質からなる群から選択される少なくとも1種を含有させることができる。
この場合、上記タンパク質としては、乳タンパク質を選択することができる。
また、上記糖質としては、単糖、二糖およびオリゴ糖からなる群から選択される少なくとも1種を選択することができる。
さらに、前記経口組成物は、腸内細菌叢の改善、免疫調節、下痢、便秘、肥満、又は炎症性腸疾患の予防及び/又は治療に用いることができる。
Next, with this technology,
An oral composition comprising at least one bacterium selected from the group consisting of Bifidobacterium and lactic acid bacteria is provided.
The oral composition according to the present technology may further contain at least one selected from the group consisting of proteins and carbohydrates.
In this case, milk protein can be selected as the protein.
Moreover, as said saccharide | sugar, at least 1 sort (s) selected from the group which consists of a monosaccharide, a disaccharide, and an oligosaccharide can be selected.
Furthermore, the oral composition can be used for improving gut microbiota, immune regulation, diarrhea, constipation, obesity, or prevention and / or treatment of inflammatory bowel disease.
本技術では、更に、ビフィドバクテリウム属細菌及び乳酸菌からなる群から選択される少なくとも1種の細菌と、ボタンボウフウと、を共存させる工程を有する、ビフィドバクテリウム属細菌および/または乳酸菌の増殖促進および/または減少抑制方法を提供する。
本技術に係る増殖促進および/または減少抑制方法では、さらにタンパク質および糖質からなる群から選択される少なくとも1種を共存させることもできる。
この場合、上記タンパクとしては、乳タンパク質を選択することができる。
また、上記糖質としては、単糖、二糖およびオリゴ糖からなる群から選択される少なくとも1種を選択することができる。
In the present technology, a Bifidobacterium bacterium and / or a lactic acid bacterium further comprising a step of coexisting at least one bacterium selected from the group consisting of a Bifidobacterium bacterium and a lactic acid bacterium and a button bud. A method for promoting proliferation and / or suppressing decrease is provided.
In the method for promoting growth and / or suppressing decrease according to the present technology, at least one selected from the group consisting of proteins and carbohydrates can be allowed to coexist.
In this case, milk protein can be selected as the protein.
Moreover, as said saccharide | sugar, at least 1 sort (s) selected from the group which consists of a monosaccharide, a disaccharide, and an oligosaccharide can be selected.
本技術によれば、ビフィズス菌や乳酸菌が増殖したり菌数に変化がない環境下においては増殖を促進させ、生存または生育(増殖)しにくい環境下においては減少を抑制させることができる。なお、ここに記載された効果は、必ずしも限定されるものではなく、本技術中に記載されたいずれかの効果であってもよい。 According to the present technology, it is possible to promote proliferation in an environment in which bifidobacteria and lactic acid bacteria grow or have no change in the number of bacteria, and to suppress a decrease in an environment in which it is difficult to survive or grow (grow). In addition, the effect described here is not necessarily limited, and may be any effect described in the present technology.
以下、本技術を実施するための好適な実施形態について説明する。なお、以下に説明する実施形態は、本開示の代表的な実施形態の一例を示したものであり、これにより本技術の範囲が狭く解釈されることはない。なお、本明細書において、数値範囲を「下限〜上限」で表現するものに関しては、上限は「以下」であっても「未満」であってもよく、下限は「以上」であっても「超」であってもよい。 Hereinafter, preferred embodiments for carrying out the present technology will be described. In addition, embodiment described below shows an example of typical embodiment of this indication, and, thereby, the range of this technique is not interpreted narrowly. In the present specification, regarding what expresses a numerical range as “lower limit to upper limit”, the upper limit may be “below” or “less than”, and the lower limit may be “more than”. It may be “super”.
1.増殖促進および/または減少抑制剤
本技術に係る増殖促進および/または減少抑制剤(以下、単に「増殖促進・減少抑制剤」とも称する)は、ボタンボウフウを有効成分とする製剤であって、ビフィズス菌および乳酸菌からなる群から選択される少なくとも1種の細菌(以下、単に「ビフィズス菌および/または乳酸菌」または「ビフィズス菌/乳酸菌」と称する)の増殖を促進する作用効果および/または減少を抑制する効果を有することを特徴とする。また本技術の増殖促進および/または減少抑制剤は、ボタンボウフウに加えて、タンパク質および糖質からなる群から選択される少なくとも1種を含有していてもよい。
以下、本技術について詳細に説明する。
1. Growth-promoting and / or decrease inhibitor The growth-promoting and / or decrease-inhibiting agent according to the present technology (hereinafter, also simply referred to as “proliferation-promoting / decrease-inhibiting agent”) is a preparation containing button bowfish as an active ingredient, Effect and / or suppression of promoting the growth of at least one bacterium selected from the group consisting of bacteria and lactic acid bacteria (hereinafter simply referred to as “Bifidobacteria and / or lactic acid bacteria” or “Bifidobacteria / lactic acid bacteria”) It has the effect to do. Moreover, the growth promotion and / or decrease inhibitor of the present technology may contain at least one selected from the group consisting of proteins and carbohydrates, in addition to buttonfish.
Hereinafter, the present technology will be described in detail.
(1)ビフィズス菌
本技術が対象とするビフィズス菌としては、例えばビフィドバクテリウム・ラクティス(Bifidobacterium lactis)、ビフィドバクテリウム・ロンガム(Bifidobacterium longum)、ビフィドバクテリウム・インファンティス(Bifidobacterium infantis)、ビフィドバクテリウム・アドレセンティス(Bifidobacterium adolescentis)、ビフィドバクテリウム・ブレーベ(Bifidobacterium breve)、ビフィドバクテリウム・ビフィダム(Bifidobacterium bifidum)、ビフィドバクテリウム・アニマリス(Bifidobacterium animalis)などが挙げられる。これらのビフィズス菌は一種単独を対象にしてもよいし、また二種以上を任意に組み合わせて対象とすることもできる。制限はされないものの、好ましくは、ビフィドバクテリウム・ロンガム、ビフィドバクテリウム・ブレーベ、およびビフィドバクテリウム・インファンティスを挙げることができる。より好ましくはビフィドバクテリウム・ロンガム、およびビフィドバクテリウム・ブレーベである。
(1) Bifidobacterium Bifidobacterium targeted by the present technology includes, for example, Bifidobacterium lactis, Bifidobacterium longum, Bifidobacterium infantis (Bifidobacterium infantis) ), Bifidobacterium adolescentis, Bifidobacterium breve, Bifidobacterium bifidum, Bifidobacterium animalis, etc. . These bifidobacteria may be used alone or in any combination of two or more. Although not limited, Bifidobacterium longum, Bifidobacterium breve, and Bifidobacterium infantis are preferable. Bifidobacterium longum and Bifidobacterium breve are more preferable.
(2)乳酸菌
本技術が対象とする乳酸菌としては、例えばラクトコッカス・ラクチス・サブスピーシーズ・ラクティス(Lactococcus lactis subsp. lactis)、ラクトコッカス・ラクティス・サブスピーシーズ・クレモリス(Lactococcus lactis subsp. cremoris)(以上、ラクトコッカス属細菌);ストレプトコッカス・サリバリウス・サブスピーシーズ・サーモフィラス(Streptococcus salivarius subsp. thermophilus)(以上、ストレプトコッカス属細菌、エンテロコッカス属細菌とも称する);リューコノストック・メセンテロイデス・サブスピーシーズ・クレモリス(Leuconostoc mesenteroides subsp. cremoris)(以上、リューコノストック属細菌);ラクトバシラス・アシドフィラス(Lactobacillus acidophilus)、ラクトバシラス・カゼイ(Lactobacillus casei)、ラクトバシラス・デルブルギ・サブスピーシーズ・ブルガリカス(Lactobacillus delbrueckii subsp. bulgaricus)、ラクトバシラス・デルブルギ・サブスピーシーズ・ラクティス(Lactobacillus delbrueckii subsp. lactis)、ラクトバシラス・ガセリ(Lactobacillus gasseri)、ラクトバシラス・ヘルベティカス(Lactobacillus helveticus)、ラクトバシラス・プランタラム(Lactobacillus plantarum)、ラクトバシラス・ブレビス(Lactobacillus brevis)、ラクトバシラス・カゼイ・サブスピーシーズラムノーサス(Lactobacillus casei subsp. rhamnosus)、ラクトバシラス・パラカゼイ(Lactobacillus paracasei)(以上、ラクトバシラス属細菌);テトラジェノコッカス・ハロフィルス(Tetragenococcus halophilus)(以上、テトラジェノコッカス属細菌)、およびペディオコッカス・ペントサセウス(Pediococcus pentosaseus)(以上、ペディオコッカス属細菌)などが挙げられる。これらの乳酸菌は一種単独を対象としてもよいし、また二種以上を任意に組み合わせて対象とすることもできる。制限はされないものの、好ましくはラクトバシラス・ガセリ、ラクトバシラス・アシドフィラス、およびラクトバシラス・パラカゼイを挙げることができる。より好ましくはラクトバシラス・パラカゼイである。
(2) Lactic acid bacteria Lactococcus lactis subsp. Cremoris (Lactococcus lactis subsp. Cremoris) (Lactococcus lactis subsp. Cremoris) Streptococcus salivarius subsp. Thermophilus (hereinafter also referred to as Streptococcus bacterium, Enterococcus bacterium); Leuconostoc mesenteroides subsp. cremoris (Leuconostock bacteria); Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus delbu Bulgaricus (Lactobacillus delbrueckii subsp. Bulgaricus), Lactobacillus delbrueckii subsp. Lactis (Lactobacillus delbrueckii subsp. Lactis), Lactobacillus gasseri (Lactobacillus gasseri), Lactobacillus helcilactus L Talam (Lactobacillus plantarum), Lactobacillus brevis (Lactobacillus brevis), Lactobacillus casei subspices rhamnosus (Lactobacillus casei subsp. Rhamnosus), Lactobacillus paracasei (Lactobacillus paracasei) (Tetragenococcus halophilus) (above, Tetragenococcus spp.) And Pediococcus pentosaseus (above, Pegococcus pentosaseus) Iokokkasu bacteria belonging to the genus), and the like. These lactic acid bacteria may be used alone or in any combination of two or more. Although not limited, Lactobacillus gasseri, Lactobacillus acidophilus, and Lactobacillus paracasei are preferable. More preferred is Lactobacillus paracasei.
(3)ボタンボウフウ
本技術が対象とするボタンボウフウ(学名:Peucedanum japonicum Thunb. var. japonicum)は、セリ科カワラボウフウ属の多年草である。別名として長命草とも呼ばれ、主に本州中部以西、四国、九州、沖縄、朝鮮南部、中国、フィリピンに分布する植物である。
(3) Button Bow The button bow (scientific name: Peucedanum japonicum Thunb. Var. Japonicum), which is the subject of this technology, is a perennial plant belonging to the genus Papaveraceae. Also known as long life grass, it is a plant distributed mainly in the west of central Honshu, Shikoku, Kyushu, Okinawa, southern Korea, China, and the Philippines.
本技術の増殖促進・減少抑制剤は、ボタンボウフウ100質量%からなるものであってもよいし、上記するように、ボタンボウフウに加えて他の成分を含有することもできる。このため、本技術の増殖促進・減少抑制剤におけるボタンボウフウの含有割合は、0.01〜100質量%の範囲で適宜調整することができ、好ましくは0.03〜100質量%、より好ましくは0.3〜100質量%、特に好ましくは3〜100質量%とすることができる。 The growth promoting / decrease suppressing agent of the present technology may be composed of 100% by weight of button fountain, and may contain other components in addition to button fountain as described above. For this reason, the content ratio of button bow fu in the growth promoting / decreasing inhibitor of the present technology can be appropriately adjusted in the range of 0.01 to 100% by mass, preferably 0.03 to 100% by mass, more preferably. It can be 0.3-100 mass%, Most preferably, it can be 3-100 mass%.
また、本技術の増殖促進・減少抑制剤は、後述する医薬品または医薬部外品や飲食品等、その最終形態に応じて、ボタンボウフウの最終濃度が0.0001〜100質量%となるような割合で、好ましくは0.03〜100質量%、特に好ましくは0.3〜100質量%となるような割合で使用することができる。 In addition, the growth promoting / decreasing agent of the present technology is such that the final concentration of button fountain is 0.0001 to 100% by mass, depending on the final form of a pharmaceutical or quasi-drug or food and drink described below It can be used in a proportion such that it is preferably 0.03 to 100 mass%, particularly preferably 0.3 to 100 mass%.
また、生体腸内のビフィズス菌および/または乳酸菌を増殖する目的および/または減少を抑制する目的で、本技術の増殖促進・減少抑制剤を経口的に摂取する場合、1日あたり摂取する量は、本技術の増殖促進・減少抑制剤に含まれるボタンボウフウの量に換算して、通常10mg〜20g/日、好ましくは30mg〜10g/日、より好ましくは1〜6g/日を挙げることができる。なお、当該摂取量は1日2回以上に分けて服用してもよい。 In addition, when taking the growth promoting / decreasing agent of the present technology orally for the purpose of growing and / or suppressing the decrease of bifidobacteria and / or lactic acid bacteria in the living intestine, the amount taken per day is In terms of the amount of button fountain contained in the growth-promoting / decrease-inhibiting agent of the present technology, 10 mg to 20 g / day, preferably 30 mg to 10 g / day, more preferably 1 to 6 g / day can be mentioned. . The intake may be divided into two or more times a day.
(4)タンパク質
前述するように、本技術の増殖促進・減少抑制剤には、ボタンボウフウに加えて、タンパク質を配合することができる。タンパク質を配合することにより、後述する実施例に示す通り、ビフィドバクテリウム属細菌および/または乳酸菌の増殖促進および/または減少抑制の効果がより優れたものとなる。
(4) Protein As described above, the growth promoting / decreasing inhibitor of the present technology can be blended with protein in addition to buttonfish. By blending the protein, the effect of promoting the growth and / or suppressing the decrease of Bifidobacterium and / or lactic acid bacteria is further improved, as shown in the Examples described later.
本技術の増殖促進・減少抑制剤に用いることができるタンパク質としては、医療、食品等の分野において用いることが可能なタンパク質を、1種又は2種以上、自由に選択して用いることができる。具体的には、例えば、カゼインやホエイタンパク質などの乳由来のタンパク質や、大豆タンパク質などの植物由来のタンパク質が挙げられる。
カゼインとしては、例えば、市販の各種カゼイン、カゼイネート等を利用することができる。より具体的には、乳酸カゼイン、硫酸カゼイン、塩酸カゼイン、ナトリウムカゼイネート、カリウムカゼイネート、カルシウムカゼイネート、マグネシウムカゼイネート又はこれらの任意の混合物等が挙げられる。また、牛乳、脱脂乳、全脂粉乳、脱脂粉乳から常法により精製したカゼイン等を利用することもできる。
ホエイタンパク質としては、市販品又は牛乳、脱脂乳等から公知の方法により分離されたホエイ(例えば、ホエイ粉末、脱塩ホエイ粉末等)又は、分離精製した乳清蛋白質濃縮物、乳清蛋白質単離物、若しくはこれらの任意の割合の混合物を用いることができる。
これらのタンパク質は、タンパク質として精製された形態で用いることもできるが、これらのタンパク質を含む原料の形態で用いることもできる。
As a protein that can be used in the growth promoting / decrease suppressing agent of the present technology, one or more proteins that can be used in the fields of medicine and food can be freely selected and used. Specifically, for example, proteins derived from milk such as casein and whey protein, and proteins derived from plants such as soybean protein can be mentioned.
Examples of casein that can be used include various commercially available caseins and caseinates. More specifically, lactate casein, sulfate casein, casein hydrochloride, sodium caseinate, potassium caseinate, calcium caseinate, magnesium caseinate, or any mixture thereof can be used. Moreover, casein etc. refine | purified by the conventional method from cow's milk, skim milk, whole fat milk powder, and skim milk powder can also be utilized.
As whey protein, whey (eg, whey powder, desalted whey powder, etc.) separated from commercially available products or from milk, skim milk, etc. by a known method, or separated and purified whey protein concentrate, whey protein isolated Or mixtures of these in any proportions.
These proteins can be used in a purified form as a protein, but can also be used in the form of a raw material containing these proteins.
乳由来のタンパク質を含む原料としては、生乳、牛乳、水牛乳、やぎ乳、羊乳、馬乳、濃縮乳、脱脂濃縮乳、脱脂粉乳、乳清蛋白質濃縮物(WPC)、乳清蛋白質分離物(WPI)、乳蛋白質濃縮物(MPC)、ミセラカゼインアイソレート(MCI)、ミルクプロテインアイソレート(MPI)等が挙げられる。 Raw materials containing milk-derived proteins include raw milk, milk, buffalo milk, goat milk, sheep milk, horse milk, concentrated milk, skim concentrated milk, skim milk powder, whey protein concentrate (WPC), and whey protein isolate. (WPI), milk protein concentrate (MPC), micellar casein isolate (MCI), milk protein isolate (MPI) and the like.
本技術でいう「乳」には「乳および乳製品の成分規格等に関する厚生労働省令」(以下、単に「乳等省令」と称する)で規定されている生乳、牛乳、特別牛乳、生山羊乳、殺菌山羊乳、部分脱脂乳、脱脂乳および加工乳の他(以上、哺乳動物の母乳)等が含まれる。これらは一種単独で本技術の増殖促進剤に配合することもできるし、また二種以上を任意に組み合わせて配合することもできる。好ましくは上記哺乳動物の母乳および豆乳であり、より好ましくは牛に由来する生乳、牛乳、特別牛乳、部分脱脂乳、脱脂乳および加工乳;並びに豆乳である。なお、上記「生乳、牛乳、特別牛乳、生山羊乳、殺菌山羊乳、部分脱脂乳、脱脂乳および加工乳」の定義は乳等省令によるものとする。 “Milk” in this technology includes raw milk, milk, special milk, and raw goat milk stipulated in the “Ministry of Health, Labor and Welfare Ordinance on Component Standards for Milk and Dairy Products” (hereinafter simply referred to as “Ministerial Ordinance for Milk”) , Pasteurized goat milk, partially skimmed milk, skimmed milk and processed milk (mammalian breast milk). These may be used alone or in combination with the growth promoter of the present technology, or two or more thereof may be combined arbitrarily. Preferred are breast milk and soy milk of the above mammals, more preferably raw milk derived from cattle, cow milk, special cow milk, partially skimmed milk, skimmed milk and processed milk; and soy milk. The definition of “raw milk, milk, special milk, raw goat milk, pasteurized goat milk, partially skimmed milk, skimmed milk and processed milk” is as defined by a ministerial ordinance such as milk.
ちなみに牛乳の平均的組成は、タンパク質3.3質量%、脂質3.8質量%、炭水化物4.8質量%、ミネラル(カリウム、カルシウム、リン酸塩、マグネシウム、ナトリウム、クエン酸塩、リン、鉄等)0.37質量%、ビタミン(ビタミンA、B1、B2、CおよびE)、および水分であり、100グラム当り約67Kカロリーである。牛乳に含まれるタンパク質の約80質量%はカゼイン(カゼインミセル)である。残りの20質量%は乳漿蛋白(ホエイプロテイン)であり、この中には、β−ラクトグロブリン、α−ラクトグロブリン、免疫グロブリン、血清アルブミン、およびラクフェリン等のタンパク質が含まれる。牛乳に含まれる炭水化物としては、乳糖(二糖)、グルコース、ガラクトース(以上、単糖)、その他のオリゴ糖を挙げることができる。炭水化物の多くは乳糖であり、脱脂粉乳の固形分のうち50質量%を占める。脱脂粉乳(固形分)の残り50質量%の多くはタンパク質である。 By the way, the average composition of milk is 3.3% protein, 3.8% lipid, 4.8% carbohydrate, minerals (potassium, calcium, phosphate, magnesium, sodium, citrate, phosphorus, iron) Etc.) 0.37% by weight, vitamins (vitamins A, B1, B2, C and E), and water, about 67K calories per 100 grams. About 80% by mass of the protein contained in milk is casein (casein micelle). The remaining 20% by mass is whey protein, which includes proteins such as β-lactoglobulin, α-lactoglobulin, immunoglobulin, serum albumin, and lactoferrin. Examples of the carbohydrate contained in milk include lactose (disaccharide), glucose, galactose (above, monosaccharide), and other oligosaccharides. Most carbohydrates are lactose and occupy 50 mass% of solid content of skim milk powder. Most of the remaining 50% by mass of skim milk powder (solid content) is protein.
植物由来のタンパク質を含む原料としては、豆乳、アーモンドミルク、ココナッツミルクなどを挙げることができる。なお、本発明において用いられる豆乳、アーモンドミルク、ココナッツミルクなどは「植物由来の乳」と定義することがある。
豆乳は、大豆を水に浸してすりつぶし、水を加えて煮つめた汁を漉したものである。
アーモンドミルクは、水に浸したアーモンドをミキサーなどで砕き、水を加えてガーゼなどで滓を漉したものである。
ココナッツミルクは、成熟したココナッツの種子の内側に、層状に形成される固形胚乳から得られる甘い乳状の食材である。
Examples of raw materials containing plant-derived proteins include soy milk, almond milk, and coconut milk. The soy milk, almond milk, coconut milk and the like used in the present invention may be defined as “plant-derived milk”.
Soy milk is made by soaking soybeans in water and adding the water to the soup.
Almond milk is made by crushing almonds soaked in water with a mixer, adding water, and rinsing them with gauze.
Coconut milk is a sweet milky ingredient obtained from solid endosperm that is layered inside mature coconut seeds.
また、本技術の増殖促進・減少抑制剤には、タンパク質を含む原料を更に加工した製品(例えば、乳製品等)を配合することもできる。
乳製品とは、前述する乳(好ましくは生乳および豆乳)を人為的に加工した可食性製品を意味する。例えば生乳から調製される乳製品としては、クリーム、バター、バターオイル、チーズ、濃縮ホエイ、アイスクリーム類(アイスクリーム、ラクトアイス、アイスミルク)、濃縮乳、脱脂濃縮乳、無糖れん乳、無糖脱脂れん乳、加糖れん乳、加糖脱脂れん乳、全粉乳、脱脂粉乳、クリームパウダー、ホエイパウダー、バターミルクパウダー、加糖粉乳、調整粉乳、発酵乳、乳酸菌飲料(無脂乳固形分3%以上を含むものに限る)および乳飲料を挙げることができる。これら各成分の定義は乳等省令によるものとする。なかでも好ましくは脱脂乳(ホエイ、濃縮ホエイ、カッテージチーズ、脱脂濃縮乳、無糖脱脂れん乳、加糖脱脂れん乳、脱脂濃縮乳、無糖脱脂れん乳、加糖脱脂れん乳、脱脂粉乳、ホエイパウダー)、粉乳(全粉乳、脱脂粉乳、クリームパウダー、ホエイパウダー、バターミルクパウダー、加糖粉乳、調整粉乳)であり、より好ましくは脱脂粉乳、ホエイパウダーである。
Moreover, the product (for example, dairy product etc.) which processed the raw material containing protein further can also be mix | blended with the proliferation promotion / decrease inhibitor of this technique.
The dairy product means an edible product obtained by artificially processing the aforementioned milk (preferably raw milk and soy milk). For example, dairy products prepared from raw milk include cream, butter, butter oil, cheese, concentrated whey, ice cream (ice cream, lacto ice, ice milk), concentrated milk, defatted concentrated milk, sugar-free milk, sugar-free Skim milk, sweetened milk, sweetened skim milk, whole milk powder, skim milk powder, cream powder, whey powder, buttermilk powder, sweetened powdered milk, adjusted powdered milk, fermented milk, lactic acid bacteria beverage (non-fat milk solid content 3% or more And dairy drinks). The definition of each of these components shall be based on the ordinance of milk. Among these, non-fat milk (whey, concentrated whey, cottage cheese, non-fat concentrated milk, sugar-free skim milk, sweetened skim milk, non-fat concentrated milk, sugar-free skim milk, sweetened skim milk, non-fat dry milk, whey powder ), Powdered milk (whole powdered milk, skim milk powder, cream powder, whey powder, buttermilk powder, sweetened powdered milk, adjusted powdered milk), and more preferably skim milk powder and whey powder.
本技術の増殖促進・減少抑制剤にタンパク質を配合する場合、その配合量は特に限定されず、ボタンボウフウの量や使用目的等に応じて、自由に設定することができる。本技術では特に、ボタンボウフウ100質量部に対して1〜10000質量部配合することが好ましく、50〜300質量部配合することがより好ましい。 When protein is blended with the growth promoting / decreasing inhibitor of the present technology, the blending amount is not particularly limited, and can be freely set according to the amount of button fountain and the purpose of use. In particular, in the present technology, it is preferable to add 1 to 10000 parts by mass, and more preferably 50 to 300 parts by mass with respect to 100 parts by mass of the button bow.
(5)糖質
前述するように、本技術の増殖促進・減少抑制剤には、ボタンボウフウに加えて、糖質を配合することができる。糖質を配合することにより、後述する実施例に示す通り、ビフィドバクテリウム属細菌および/または乳酸菌の増殖促進および/または減少抑制の効果がより優れたものとなる。
(5) Carbohydrate As described above, the growth promoting / decreasing inhibitor of the present technology may contain a sugar in addition to the button bow. By adding a saccharide, the effect of promoting the growth and / or suppressing the decrease of Bifidobacterium and / or lactic acid bacteria is further improved, as shown in the Examples described later.
本技術の増殖促進・減少抑制剤に用いることができる糖質としては、医療、食品等の分野において用いることが可能な糖質を、1種又は2種以上、自由に選択して用いることができる。具体的には、例えば、グルコース、フルクトース、ガラクトース、ラムノースおよびフコース等の単糖;乳糖(ラクトース)、スクロース、マルトースおよびトレハロース等の二糖;ラフィノース等の三糖;ラクチュロース、フラクトオリゴ糖、ガラクトオリゴ糖、マンナンオリゴ糖、イソマルトオリゴ糖、キシロオリゴ糖等のオリゴ糖;N−アセチルグルコサミン、デキストリン、大豆オリゴ糖等の多糖類を挙げることができる。好ましくは単糖、二糖およびオリゴ糖であり、より好ましくはグルコース、および乳糖を挙げることができる。なお、ラクチュロースは、乳糖を公知の方法でアルカリ異性化したものであり、商業的に入手することができるが、特公昭52−21063号公報に記載の方法に従って製造することもできる。 As the carbohydrate that can be used in the growth promoting / decreasing agent of the present technology, one or two or more carbohydrates that can be used in the fields of medicine, food, etc., can be freely selected and used. it can. Specifically, for example, monosaccharides such as glucose, fructose, galactose, rhamnose and fucose; disaccharides such as lactose, sucrose, maltose and trehalose; trisaccharides such as raffinose; lactulose, fructooligosaccharides, galactooligosaccharides, Examples thereof include oligosaccharides such as mannan oligosaccharide, isomaltoligosaccharide and xylooligosaccharide; polysaccharides such as N-acetylglucosamine, dextrin and soybean oligosaccharide. Preferred are monosaccharides, disaccharides and oligosaccharides, and more preferred are glucose and lactose. Lactulose is obtained by alkaline isomerization of lactose by a known method, and can be obtained commercially, but can also be produced according to the method described in Japanese Patent Publication No. Sho 52-21063.
本技術の増殖促進・減少抑制剤に糖質を配合する場合、その配合量は特に限定されず、ボタンボウフウの量や使用目的等に応じて、自由に設定することができる。本技術では特に、ボタンボウフウ100質量部に対して1〜20000質量部配合することが好ましく、80〜500質量部配合することがより好ましい。 When a saccharide is blended in the growth promoting / decreasing inhibitor of the present technology, the blending amount is not particularly limited, and can be freely set according to the amount of button fountain and the purpose of use. In this technique, it is preferable to mix | blend 1-20000 mass parts especially with respect to 100 mass parts of button bow fu, and it is more preferable to mix | blend 80-500 mass parts.
(6)その他の成分
本技術の増殖促進・減少抑制剤には、本技術の効果を損なわない限り、医療、食品等の分野において使用可能なその他の成分を、1種又は2種以上、自由に選択して用いることができる。
(6) Other components The growth promoting / decreasing inhibitor of this technology is free of one or more other components that can be used in the fields of medicine, food, etc., as long as the effects of this technology are not impaired. Can be selected and used.
他の成分としては、ボタンボウフウを製剤化するために使用される担体及び添加剤を挙げることができる。具体的には、例えば、賦形剤、pH調整剤、着色剤、矯味剤等の成分を用いることができる。また、公知の又は将来的に見出される疾患や症状の予防、改善及び/又は治療の効果を有する成分を、適宜目的に応じて併用することも可能である。 Other ingredients can include carriers and additives used to formulate button buds. Specifically, for example, components such as an excipient, a pH adjuster, a colorant, and a corrigent can be used. Moreover, it is also possible to use together the component which has the effect of prevention, improvement, and / or treatment of the well-known disease or symptom discovered in the future according to the objective suitably.
前記製剤担体としては、剤形に応じて、各種有機又は無機の担体を用いることができる。固形製剤の場合の担体としては、例えば、賦形剤、結合剤、崩壊剤、滑沢剤、安定剤、矯味矯臭剤等が挙げられる。 As the preparation carrier, various organic or inorganic carriers can be used depending on the dosage form. Examples of the carrier in the case of a solid preparation include excipients, binders, disintegrants, lubricants, stabilizers, and flavoring agents.
前記賦形剤としては、例えば、乳糖、白糖、ブドウ糖、マンニット、ソルビット等の糖誘導体;トウモロコシデンプン、馬鈴薯デンプン、α−デンプン、デキストリン、カルボキシメチルデンプン等のデンプン誘導体;結晶セルロース、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、カルボキシメチルセルロース、カルボキシメチルセルロースカルシウム等のセルロース誘導体;アラビアゴム;デキストラン;プルラン;軽質無水珪酸、合成珪酸アルミニウム、メタ珪酸アルミン酸マグネシウム等の珪酸塩誘導体;リン酸カルシウム等のリン酸塩誘導体;炭酸カルシウム等の炭酸塩誘導体;硫酸カルシウム等の硫酸塩誘導体等が挙げられる。 Examples of the excipient include sugar derivatives such as lactose, sucrose, glucose, mannitol and sorbit; starch derivatives such as corn starch, potato starch, α-starch, dextrin and carboxymethyl starch; crystalline cellulose and hydroxypropylcellulose Cellulose derivatives such as hydroxypropylmethylcellulose, carboxymethylcellulose, carboxymethylcellulose calcium; gum arabic; dextran; pullulan; silicate derivatives such as light anhydrous silicic acid, synthetic aluminum silicate, magnesium magnesium magnesium silicate; phosphate derivatives such as calcium phosphate; Examples thereof include carbonate derivatives such as calcium carbonate; sulfate derivatives such as calcium sulfate.
前記結合剤としては、例えば、上記賦形剤の他、ゼラチン;ポリビニルピロリドン;マクロゴール等が挙げられる。 Examples of the binder include gelatin, polyvinyl pyrrolidone, macrogol and the like in addition to the excipients described above.
前記崩壊剤としては、例えば、上記賦形剤の他、クロスカルメロースナトリウム、カルボキシメチルスターチナトリウム、架橋ポリビニルピロリドン等の化学修飾されたデンプン又はセルロース誘導体等が挙げられる。 Examples of the disintegrant include, in addition to the above excipients, chemically modified starch or cellulose derivatives such as croscarmellose sodium, carboxymethyl starch sodium, and crosslinked polyvinylpyrrolidone.
前記滑沢剤としては、例えば、タルク;ステアリン酸;ステアリン酸カルシウム、ステアリン酸マグネシウム等のステアリン酸金属塩;コロイドシリカ;ピーガム、ゲイロウ等のワックス類;硼酸;グリコール;フマル酸、アジピン酸等のカルボン酸類;安息香酸ナトリウム等のカルボン酸ナトリウム塩;硫酸ナトリウム等の硫酸塩類;ロイシン;ラウリル硫酸ナトリウム、ラウリル硫酸マグネシウム等のラウリル硫酸塩;無水珪酸、珪酸水和物等の珪酸類;デンプン誘導体等が挙げられる。 Examples of the lubricant include talc; stearic acid; stearic acid metal salts such as calcium stearate and magnesium stearate; colloidal silica; waxes such as pea gum and gallow; boric acid; glycol; carboxyl such as fumaric acid and adipic acid Acids; sodium carboxylic acid salts such as sodium benzoate; sulfates such as sodium sulfate; leucine; lauryl sulfates such as sodium lauryl sulfate and magnesium lauryl sulfate; silicic acids such as anhydrous silicic acid and silicic acid hydrate; starch derivatives, etc. Can be mentioned.
前記安定剤としては、例えば、メチルパラベン、プロピルパラベン等のパラオキシ安息香酸エステル類;クロロブタノール、ベンジルアルコール、フェニルエチルアルコール等のアルコール類;塩化ベンザルコニウム;無水酢酸;ソルビン酸等が挙げられる。 Examples of the stabilizer include paraoxybenzoates such as methyl paraben and propyl paraben; alcohols such as chlorobutanol, benzyl alcohol and phenylethyl alcohol; benzalkonium chloride; acetic anhydride; sorbic acid and the like.
前記矯味矯臭剤としては、例えば、甘味料、酸味料、香料等が挙げられる。
なお、経口投与用の液剤の場合に使用する担体としては、水等の溶剤、矯味矯臭剤等が挙げられる。
Examples of the flavoring agent include sweeteners, acidulants, and fragrances.
In addition, as a carrier used in the case of a liquid for oral administration, a solvent such as water, a flavoring agent and the like can be mentioned.
(7)用途
本技術の増殖促進・減少抑制剤は、もっぱらビフィズス菌/乳酸菌の増殖を促進し、又は、減少を抑制し、当該細菌の生菌数を増加させるか、又は当該細菌の生残性を向上させる目的で使用される。
(7) Use The growth promoting / decreasing inhibitor of the present technology exclusively promotes the growth of bifidobacteria / lactic acid bacteria, suppresses the decrease, increases the number of viable bacteria, or survives the bacteria. Used to improve performance.
本技術において「増殖促進」(増殖促進作用)とは、生存可能な環境下にあるビフィズス菌/乳酸菌(生菌)に作用して、その増殖を促進することをいう。
本技術において「減少抑制」(減少抑制作用)とは、生存または生育(増殖)しにくい環境下において、当該ビフィズス菌/乳酸菌に対して増殖促進を図ることで、死滅(不活性化)による生菌数の減少を抑え、生きた状態で残存する菌体数(生菌数)を維持または増やすことができること(生残率の向上)をいう。
In the present technology, “proliferation promotion” (growth promoting action) means acting on bifidobacteria / lactic acid bacteria (live bacteria) in a viable environment to promote the growth.
In the present technology, “decrease suppression” (decrease suppression action) means that by promoting the growth of the bifidobacteria / lactic acid bacteria in an environment where it is difficult to survive or grow (proliferate), It means that the decrease in the number of bacteria can be suppressed and the number of cells remaining in the living state (viable cell count) can be maintained or increased (improvement of survival rate).
本技術の増殖促進・減少抑制剤が有するこうした増殖促進作用および減少抑制作用は、本技術の増殖促進・減少抑制剤の存在下でビフィズス菌/乳酸菌(生菌)を培養した場合に、培養前後のビフィズス菌/乳酸菌の生菌数の割合をもとにした下式で算出される生残率(%)が、本技術の増殖促進・減少抑制剤非存在下でビフィズス菌/乳酸菌(生菌)を培養した場合に算出される生残率(%)(対照生残率)と比較して、高いことを指標として判断することができる。なお、本明細書における「培養」とは、ビフィズス菌/乳酸菌が増殖するために必要な栄養素が含まれずに本技術の増殖促進・減少抑制剤のみの存在下で、ビフィズス菌/乳酸菌が生育可能な温度で維持される状態も含まれる。
ビフィズス菌/乳酸菌の具体的な培養方法や条件は後述する実験例に記載する方法を参考にすることができる。
These growth promotion and reduction inhibitory effects of the growth promotion / reduction inhibitor of this technology are the same as before and after the culture when bifidobacteria / lactic acid bacteria (viable bacteria) are cultured in the presence of the growth promotion / reduction inhibitor of this technology. The survival rate (%) calculated from the ratio of the number of viable Bifidobacteria / Lactic acid bacteria in the following formula is calculated in the absence of the growth promoting / decreasing inhibitor of this technology. ) Can be judged as an index compared to the survival rate (%) (control survival rate) calculated when cultivating. In this specification, “culture” means that the bifidobacteria / lactic acid bacteria can grow in the presence of only the growth-promoting / decrease-inhibiting agent of this technology without the nutrients necessary for the growth of bifidobacteria / lactic acid bacteria. The state maintained at various temperatures is also included.
The specific culture method and conditions of bifidobacteria / lactic acid bacteria can refer to the methods described in the experimental examples described later.
[数1]
生残率(%)=[培養後の生菌数/培養前の生菌数]×100
[Equation 1]
Survival rate (%) = [number of viable cells after cultivation / number of viable cells before cultivation] × 100
なお、生残率(%)の算出にあたり、ビフィズス菌/乳酸菌の生菌数の求め方は定法に基づいて実施することができる。生菌数の測定法としては、ビフィズス菌測定法として、TOSプロピオン酸寒天培地(ヤクルト薬品工業株式会社)を使用したコロニー計数法が挙げられる。乳酸菌測定法として、BCP加プレートカウント寒天培地”栄研”(栄研化学株式会社)を使用したコロニー計数法が挙げられる。 In calculating the survival rate (%), the number of viable bacteria of bifidobacteria / lactic acid bacteria can be determined based on a standard method. Examples of the method for measuring the number of viable bacteria include a colony counting method using a TOS propionic acid agar medium (Yakult Pharmaceutical Co., Ltd.) as a method for measuring bifidobacteria. An example of a method for measuring lactic acid bacteria is a colony counting method using a BCP-added plate count agar medium “Eiken” (Eiken Chemical Co., Ltd.).
本技術の増殖促進・減少抑制剤は、ビフィズス菌/乳酸菌の増殖を促進し、又は、減少を抑制することにより、腸内細菌叢の改善、免疫調節、下痢、便秘、肥満、又は炎症性腸疾患等の予防及び/又は治療に有用であるので、これらの用途に基づく医薬品又は医薬部外品、飲食品、及び飼料等の形態で用いることができる。 The growth promoting / decreasing agent of the present technology promotes the growth of bifidobacteria / lactic acid bacteria or suppresses the decrease, thereby improving intestinal flora, immune regulation, diarrhea, constipation, obesity, or inflammatory bowel Since it is useful for prevention and / or treatment of diseases and the like, it can be used in the form of pharmaceuticals or quasi-drugs, foods and drinks, and feeds based on these uses.
(7−1)医薬品、医薬部外品
本技術に係る増殖促進・減少抑制剤は、その優れたビフィズス菌/乳酸菌の増殖促進・減少抑制効果を利用して、ヒト若しくは動物用の医薬品、医薬部外品等の有効成分として、これらに配合して使用可能である。
(7-1) Drugs and Quasi-drugs Growth-promoting / decrease-inhibiting agents according to the present technology are used for human or veterinary drugs, pharmaceuticals by utilizing the excellent bifidobacteria / lactic acid-bacteria growth-promoting / decreasing effect. It can be blended and used as an active ingredient such as quasi-drug.
医薬品に配合する場合、該医薬品は、経口投与や非経口投与などの投与方法に応じて、適宜所望の剤形に製剤化することができる。その剤形は特に限定されないが、経口投与の場合、例えば、散剤、顆粒剤、錠剤、トローチ剤、カプセル剤等の固形製剤;溶液剤、シロップ剤、懸濁剤、乳剤等の液剤等に製剤化することができる。非経口投与の場合、例えば、座剤、噴霧剤、吸入剤、軟膏剤、貼付剤、注射剤等に製剤化することができる。本開示では、経口投与の剤形に製剤化することが好ましい。
なお、製剤化は剤形に応じて、適宜、公知の方法により実施できる。
When blended with a pharmaceutical product, the pharmaceutical product can be appropriately formulated into a desired dosage form according to an administration method such as oral administration or parenteral administration. The dosage form is not particularly limited, but for oral administration, for example, solid preparations such as powders, granules, tablets, troches and capsules; liquid preparations such as solutions, syrups, suspensions and emulsions. Can be In the case of parenteral administration, it can be formulated into, for example, suppositories, sprays, inhalants, ointments, patches, injections and the like. In the present disclosure, it is preferable to formulate into a dosage form for oral administration.
The formulation can be appropriately performed by a known method depending on the dosage form.
(7−2)飲食品
本技術に係る増殖促進・減少抑制剤は、その優れたビフィズス菌/乳酸菌の増殖促進・減少抑制効果を利用して、ヒト若しくは動物用の健康食品、機能性食品、病者用食品、経腸栄養食品、特別用途食品、保健機能食品、特定保健用食品、機能性表示食品、栄養機能食品等の有効成分として、これらに配合して使用可能である。
(7-2) Food / beverage products The growth promoting / decreasing inhibitor according to the present technology uses the excellent bifidobacteria / lactic acid bacteria growth promoting / decreasing effect, and is a health food for humans or animals, a functional food, It can be used in combination with these as active ingredients such as foods for the sick, enteral nutritional foods, special purpose foods, functional health foods, foods for specified health use, functional indication foods, and functional nutritional foods.
本技術に係る増殖促進・減少抑制剤は、公知の飲食品に添加して調製することもできるし、飲食品の原料中に混合して新たな飲食品を製造することもできる。 The proliferation promoting / decreasing inhibitor according to the present technology can be prepared by adding to a known food or drink, or can be mixed with a raw material of a food or drink to produce a new food or drink.
前記飲食品は、液状、ペースト状、固体、粉末等の形態を問わず、錠菓、流動食等のほか、例えば、小麦粉製品、即席食品、農産加工品、水産加工品、畜産加工品、乳・乳製品、油脂類、基礎調味料、複合調味料・食品類、冷凍食品、菓子類、飲料、これら以外の市販品等が挙げられる。 The food and drink may be in the form of liquid, paste, solid, powder, etc., in addition to tablet confectionery, liquid food, etc., for example, flour products, instant foods, processed agricultural products, processed fishery products, processed livestock products, milk -Dairy products, fats and oils, basic seasonings, compound seasonings / foods, frozen foods, confectionery, beverages, commercial products other than these.
前記小麦粉製品としては、例えば、パン、マカロニ、スパゲッティ、めん類、ケーキミックス、から揚げ粉、パン粉等が挙げられる。
前記即席食品類としては、例えば、即席めん、カップめん、レトルト・調理食品、調理缶詰め、電子レンジ食品、即席スープ・シチュー、即席みそ汁・吸い物、スープ缶詰め、フリーズ・ドライ食品、その他の即席食品等が挙げられる。
前記農産加工品としては、例えば、農産缶詰め、果実缶詰め、ジャム・マーマレード類、漬物、煮豆類、農産乾物類、シリアル(穀物加工品)等が挙げられる。
前記水産加工品としては、例えば、水産缶詰め、魚肉ハム・ソーセージ、水産練り製品、水産珍味類、つくだ煮類等が挙げられる。
前記畜産加工品としては、例えば、畜産缶詰め・ペースト類、畜肉ハム・ソーセージ等が挙げられる。
前記乳・乳製品としては、例えば、加工乳、乳飲料、ヨーグルト類、乳酸菌飲料類、チーズ、アイスクリーム類、調製粉乳類、クリーム、その他の乳製品等が挙げられる。
前記油脂類としては、例えば、バター、マーガリン類、植物油等が挙げられる。
前記基礎調味料としては、例えば、しょうゆ、みそ、ソース類、トマト加工調味料、みりん類、食酢類等が挙げられ、前記複合調味料・食品類として、調理ミックス、カレーの素類、たれ類、ドレッシング類、めんつゆ類、スパイス類、その他の複合調味料等が挙げられる。
前記冷凍食品としては、例えば、素材冷凍食品、半調理冷凍食品、調理済冷凍食品等が挙げられる。
前記菓子類としては、例えば、キャラメル、キャンディー、チューインガム、チョコレート、クッキー、ビスケット、ケーキ、パイ、スナック、クラッカー、和菓子、米菓子、豆菓子、デザート菓子、その他の菓子等が挙げられる。
前記飲料としては、例えば、炭酸飲料、天然果汁、果汁飲料、果汁入り清涼飲料、果肉飲料、果粒入り果実飲料、野菜系飲料、豆乳、豆乳飲料、コーヒー飲料、お茶飲料、粉末飲料、濃縮飲料、スポーツ飲料、栄養飲料、アルコール飲料、その他の嗜好飲料等が挙げられる。
上記以外の市販食品としては、例えば、ベビーフード、ふりかけ、お茶潰けのり等が挙げられる。
Examples of the flour product include bread, macaroni, spaghetti, noodles, cake mix, fried flour, bread crumbs and the like.
Examples of the instant foods include instant noodles, cup noodles, retort / cooked food, cooking canned food, microwave food, instant soup / stew, instant miso soup / soup, canned soup, freeze-dried food, other instant foods, etc. Can be mentioned.
Examples of the processed agricultural products include canned agricultural products, canned fruits, jams and marmalades, pickles, boiled beans, dried agricultural products, and cereals (cereal processed products).
Examples of the processed fishery products include canned fishery products, fish hams and sausages, fishery paste products, fishery delicacies, and tsukudani.
Examples of the processed livestock products include canned livestock products / pastes, livestock meat hams / sausages, and the like.
Examples of the milk / dairy products include processed milk, milk beverages, yogurts, lactic acid bacteria beverages, cheese, ice creams, prepared milk powders, creams, and other dairy products.
Examples of the fats and oils include butter, margarines, and vegetable oils.
Examples of the basic seasonings include soy sauce, miso, sauces, tomato processed seasonings, mirins, vinegars, etc., and the mixed seasonings and foods include cooking mixes, curry ingredients, and sauces , Dressings, noodle soups, spices, and other complex seasonings.
As said frozen food, raw material frozen food, semi-cooked frozen food, cooked frozen food, etc. are mentioned, for example.
Examples of the confectionery include caramel, candy, chewing gum, chocolate, cookies, biscuits, cakes, pie, snacks, crackers, Japanese confectionery, rice confectionery, bean confectionery, dessert confectionery, and other confectionery.
Examples of the beverage include carbonated beverages, natural fruit juices, fruit juice beverages, soft drinks with fruit juice, fruit beverages, fruit beverages with fruit granules, vegetable beverages, soy milk, soy milk beverages, coffee beverages, tea beverages, powdered beverages, and concentrated beverages. Sports drinks, nutritional drinks, alcoholic drinks, other taste drinks, and the like.
Examples of commercially available foods other than the above include baby foods, sprinkles, and tea paste.
また、本開示で定義される飲食品は、特定の用途(特に保健の用途)や機能が表示された飲食品として提供・販売されることも可能である。
「表示」行為には、需要者に対して前記用途を知らしめるための全ての行為が含まれ、前記用途を想起・類推させうるような表現であれば、表示の目的、表示の内容、表示する対象物・媒体等の如何に拘わらず、全て本開示の「表示」行為に該当する。
In addition, the food and drink defined in the present disclosure can be provided and sold as a food and drink displaying specific uses (particularly health uses) and functions.
The “display” act includes all acts for informing the consumer of the use, and if the expression can remind the user of the use, the purpose of the display, the content of the display, the display Regardless of the target object / medium, etc., all fall under the “display” act of this disclosure.
また、「表示」は、需要者が上記用途を直接的に認識できるような表現により行われることが好ましい。具体的には、飲食品に係る商品又は商品の包装に前記用途を記載したものを譲渡し、引き渡し、譲渡若しくは引き渡しのために展示し、輸入する行為、商品に関する広告、価格表若しくは取引書類に上記用途を記載して展示し、若しくは頒布し、又はこれらを内容とする情報に上記用途を記載して電磁気的(インターネット等)方法により提供する行為等が挙げられる。 Moreover, it is preferable that the “display” is performed by an expression that allows the consumer to directly recognize the above-described use. Specifically, it is the act of transferring, displaying, importing, displaying, or importing products that are related to food or drinks or products that describe the use, on advertisements, price lists, or transaction documents. For example, an act of describing and displaying the above uses or distributing them, or describing the above uses in information including the contents and providing them by an electromagnetic (Internet or the like) method can be given.
一方、表示内容としては、行政等によって認可された表示(例えば、行政が定める各種制度に基づいて認可を受け、そのような認可に基づいた態様で行う表示等)であることが好ましい。また、そのような表示内容を、包装、容器、カタログ、パンフレット、POP等の販売現場における宣伝材、その他の書類等へ付することが好ましい。 On the other hand, the display content is preferably a display approved by the government or the like (for example, a display that is approved based on various systems determined by the government and performed in a mode based on such approval). Moreover, it is preferable to attach such display contents to advertising materials at sales sites such as packaging, containers, catalogs, pamphlets, POPs, and other documents.
また、「表示」には、健康食品、機能性食品、病者用食品、経腸栄養食品、特別用途食品、保健機能食品、特定保健用食品、機能性表示食品、栄養機能食品、医薬用部外品等としての表示も挙げられる。この中でも特に、消費者庁によって認可される表示、例えば、特定保健用食品制度、機能性表示食品制度、これらに類似する制度にて認可される表示等が挙げられる。より具体的には、特定保健用食品としての表示、条件付き特定保健用食品としての表示、機能性表示食品としての表示、身体の構造や機能に影響を与える旨の表示、疾病リスク低減表示等を挙げることができる。この中でも典型的な例としては、健康増進法施行規則(平成15年4月30日日本国厚生労働省令第86号)に定められた特定保健用食品としての表示(特に保健の用途の表示)、食品表示法(平成25年法律第70号)に定められた機能性表示食品としての表示及びこれらに類する表示である。 “Indications” include health foods, functional foods, foods for the sick, enteral nutritional foods, special purpose foods, health functional foods, foods for specified health use, functional labeling foods, nutritional functional foods, and pharmaceutical departments. The display as a foreign article etc. is also mentioned. Among these, in particular, indications approved by the Consumer Affairs Agency, for example, indications approved by food systems for specific health use, functional indication food systems, systems similar to these, and the like. More specifically, indication as food for specified health use, indication as conditional health food, indication as functional indication food, indication to affect body structure and function, indication of reduced disease risk, etc. Can be mentioned. A typical example of this is the indication of food for specified health use (particularly indication of health use) as stipulated in the Enforcement Regulations of the Health Promotion Act (Ministry of Health, Labor and Welfare Ordinance No. 86 of April 30, 2003) This is a display as a functional indication food defined by the Food Labeling Act (Act No. 70 of 2013) and a similar indication.
(7−3)飼料
本技術に係る増殖促進・減少抑制剤は、その優れたビフィズス菌/乳酸菌の増殖促進・減少抑制効果を利用して、動物用の飼料の有効成分として、使用可能である。本技術に係る増殖促進・減少抑制剤は、公知の飼料に添加して調製することもできるし、飼料の原料中混合して新たな飼料を製造することもできる。
(7-3) Feed The growth promoting / decreasing inhibitor according to the present technology can be used as an active ingredient of animal feed, utilizing the excellent growth promoting / decreasing inhibitory effect of bifidobacteria / lactic acid bacteria. . The growth promoting / decreasing inhibitor according to the present technology can be prepared by adding to a known feed, or can be mixed in the feed raw material to produce a new feed.
前記飼料の原料としては、例えば、トウモロコシ、小麦、大麦、ライ麦等の穀類;ふすま、麦糠、米糠、脱脂米糠等の糠類;コーングルテンミール、コーンジャムミール等の製造粕類;脱脂粉乳、ホエー、魚粉、骨粉等の動物性飼料類;ビール酵母等の酵母類;リン酸カルシウム、炭酸カルシウム等の鉱物質飼料;油脂類;アミノ酸類;糖類等が挙げられる。また、前記飼料の形態としては、例えば、愛玩動物用飼料(ペットフード等)、家畜飼料、養魚飼料等が挙げられる。 Examples of the raw material of the feed include cereals such as corn, wheat, barley, and rye; bran such as bran, wheat straw, rice bran, and defatted rice bran; and manufactured porridges such as corn gluten meal and corn jam meal; Animal feeds such as whey, fish meal and bone meal; yeasts such as beer yeast; mineral feeds such as calcium phosphate and calcium carbonate; fats and oils; amino acids; In addition, examples of the form of the feed include pet animal feed (pet food, etc.), livestock feed, fish feed, and the like.
2.経口組成物
本技術に係る経口組成物は、ボタンボウフウと、ビフィドバクテリウム属細菌および乳酸菌からなる群から選択される少なくとも1種の細菌と、を少なくとも含む組成物である。また、必要に応じて、タンパク質および糖質からなる群から選択される少なくとも1種を含有させることができる。前記経口組成物は、腸内細菌叢の改善、免疫調節、下痢、便秘、肥満、又は炎症性腸疾患等の予防及び/又は治療に用いることができる。
2. Oral composition The oral composition which concerns on this technique is a composition which contains at least button pea and at least 1 sort (s) of bacteria selected from the group which consists of Bifidobacterium genus bacteria and lactic acid bacteria. Moreover, at least 1 sort (s) selected from the group which consists of protein and carbohydrate can be contained as needed. The oral composition can be used for the prevention and / or treatment of intestinal microbiota improvement, immune regulation, diarrhea, constipation, obesity, inflammatory bowel disease and the like.
経口組成物中のビフィズス菌/乳酸菌の含有量は特に限定されず、使用目的等に応じて自由に設定することができる。本技術では、特に、経口組成物1g中にビフィズス菌および/または乳酸菌(両者を含む場合は総量)を、通常1×104cfu/g以上、好ましくは1×106〜1×1012cfu/gの範囲で含むことができる。 The content of bifidobacteria / lactic acid bacteria in the oral composition is not particularly limited, and can be freely set according to the purpose of use. In the present technology, in particular, bifidobacteria and / or lactic acid bacteria (total amount when both are included) in 1 g of the oral composition are usually 1 × 10 4 cfu / g or more, preferably 1 × 10 6 to 1 × 10 12 cfu. / G.
なお、ビフィズス菌/乳酸菌、ボタンボウフウ、タンパク質、糖類、その他の成分の詳細については、前述した増殖促進および/または減少抑制剤と同一であるため、ここでは説明を割愛する。 The details of the bifidobacteria / lactic acid bacterium, button fountain, protein, saccharide, and other components are the same as those of the growth promoting and / or reducing inhibitor described above, and thus the description thereof is omitted here.
3.ビフィズス菌/乳酸菌の増殖促進および/または減少抑制方法
本技術のビフィズス菌/乳酸菌の増殖促進および/または減少抑制方法(以下、単に「増殖促進・減少抑制方法」ともいう)は、ビフィドバクテリウム属細菌及び乳酸菌からなる群から選択される少なくとも1種の細菌と、ボタンボウフウと、を共存させる工程を有する方法である。また、必要に応じて、さらにタンパク質および糖質からなる群から選択される少なくとも1種を共存させることもできる。
3. Bifidobacteria / Lactic Acid Bacteria Growth Promotion and / or Reduction Suppression Method The Bifidobacterium / lactic acid bacteria growth promotion and / or reduction suppression method of the present technology (hereinafter, also simply referred to as “growth promotion / reduction suppression method”) is Bifidobacterium. It is a method having a step of coexisting at least one kind of bacteria selected from the group consisting of genus bacteria and lactic acid bacteria and button fountain. Moreover, at least 1 sort (s) selected from the group which consists of protein and carbohydrate can also coexist as needed.
なお、ビフィズス菌/乳酸菌、ボタンボウフウ、タンパク質、糖類、その他の成分の詳細については、前述した増殖促進および/または減少抑制剤や経口組成物と同一であるため、ここでは説明を割愛する。 The details of the bifidobacteria / lactic acid bacterium, button fountain, protein, saccharide, and other components are the same as those of the above-described growth promoting and / or decreasing inhibitor and oral composition, and thus description thereof is omitted here.
以下、実施例に基づいて本技術を更に詳細に説明する。なお、以下に説明する実施例は、本技術の代表的な実施例の一例を示したものであり、これにより本技術の範囲が狭く解釈されることはない。 Hereinafter, the present technology will be described in more detail based on examples. In addition, the Example described below shows an example of a typical example of the present technology, and the scope of the present technology is not interpreted narrowly.
<実験例1>
実験例1では、ビフィズス菌の増殖性に対するボタンボウフウの影響を調べた。
なお、ビフィズス菌として、ビフィドバクテリウム・ロンガム(Bifidobacterium longum)を用いた。より具体的には、ビフィドバクテリウム・ロンガムとしては、「BAA−999」(Bifidobacterium longum ATCC BAA-999)という寄託番号でアメリカン・タイプ・カルチャー・コレクション(ATCC)に寄託されており、商業的に入手することが可能な(http://www.atcc.org/products/all/BAA-999.aspx)菌を用いた(以下同じ)。
また、ボタンボウフウ粉末として、金秀バイオ株式会社製「与那国長命草青汁」を用いた(以下同じ)。
<Experimental example 1>
In Experimental Example 1, the effect of button bow fu on the growth of Bifidobacteria was examined.
In addition, Bifidobacterium longum (Bifidobacterium longum) was used as a Bifidobacterium. More specifically, Bifidobacterium longum has been deposited with the American Type Culture Collection (ATCC) under the deposit number “BAA-999” (Bifidobacterium longum ATCC BAA-999) and is commercially available. (Http://www.atcc.org/products/all/BAA-999.aspx) was used (hereinafter the same).
As the button bow powder, “Yonaguni Chomeizo Aojiru” manufactured by Kinshu Bio Co., Ltd. was used (hereinafter the same).
(1)各実験材料の調製
(1−1)ビフィズス菌の調製
各種ビフィズス菌を、蛋白質、アミノ酸、糖源を含有する培地に接種し、32〜41℃で5〜24時間培養を行った後、培養液から遠心分離により菌体(湿菌体)を集菌した。凍結乾燥機(共和真空社製)を用いて、18〜96時間の凍結乾燥を行い、凍結乾燥終了後の菌体塊を物理的に粉砕して各種ビフィズス菌を得た。
(1) Preparation of each experimental material (1-1) Preparation of bifidobacteria After inoculating various bifidobacteria in a medium containing protein, amino acid, and sugar source and culturing at 32-41 ° C. for 5-24 hours The cells (wet cells) were collected from the culture solution by centrifugation. Lyophilization was performed for 18 to 96 hours using a freeze dryer (manufactured by Kyowa Vacuum Co., Ltd.), and the cell mass after completion of freeze drying was physically pulverized to obtain various bifidobacteria.
(1−2)ボタンボウフウ溶液の調製
ボタンボウフウ粉末3gを水道水又は牛乳100mLに溶解してボタンボウフウ溶液を調製し、90℃で10分間オートクレーブ殺菌を行い、滅菌した。
(1-2) Preparation of button fountain solution 3 g of button fountain powder was dissolved in 100 mL of tap water or milk to prepare a button fountain solution, which was sterilized by autoclaving at 90 ° C. for 10 minutes.
(2)実験方法
試験管に入れた10mL量の各ボタンボウフウ溶液(滅菌済)に、10mLあたりの菌数が1.0×109cfu(1.0×108cfu/mL)となるように生理食塩水で希釈調整した各種ビフィズス菌を接種し、37℃で8時間および16時間培養した。培養後、培養物中の生菌数(cfu/mL)とpHを測定し、培養前の生菌数とpHと比較し、ビフィズス菌の増殖性及び生残性(生残率)に対するボタンボウフウの影響を評価した。なお、比較のため、上記ボタンボウフウ溶液に代えて、水道水又は牛乳を用いて、同様に実験を行った。
(2) Experimental method The number of bacteria per 10 mL becomes 1.0 × 10 9 cfu (1.0 × 10 8 cfu / mL) in each 10 mL amount of each button bow solution (sterilized) put in a test tube. Were inoculated with various Bifidobacterium diluted with physiological saline and cultured at 37 ° C. for 8 hours and 16 hours. After culturing, the number of viable bacteria (cfu / mL) and pH in the culture are measured, and compared with the number of viable bacteria and pH before culturing, the button fountain for the growth and survival (survival rate) of bifidobacteria The impact of. For comparison, the same experiment was performed using tap water or milk instead of the button-bowl solution.
(3)実験結果
実施例1〜2および比較例1〜2の結果を表1に示す。
(3) Experimental results Table 1 shows the results of Examples 1-2 and Comparative Examples 1-2.
実施例1と比較例1との対比からわかるように、ビフィズス菌をボタンボウフウの存在下で培養することで、ビフィズス菌の生菌数の減少が抑制され、結果的に生残率が上昇することが判明した。
また、比較例2に示すように、牛乳にはビフィズス菌の生残率を上昇させる効果があるものの、実施例2に示すように、牛乳にボタンボウフウを組み合わせることで、ビフィズス菌の菌増殖がさらに一層促進されて、生菌数が増加することが判明した。
As can be seen from the comparison between Example 1 and Comparative Example 1, by culturing bifidobacteria in the presence of button fountain, a decrease in the viable count of bifidobacteria is suppressed, and as a result, the survival rate increases. It has been found.
In addition, as shown in Comparative Example 2, although milk has an effect of increasing the survival rate of bifidobacteria, as shown in Example 2, the growth of bifidobacteria is enhanced by combining button fountain with milk. It was further promoted that the number of viable bacteria increased.
<実験例2>
実験例2では、乳酸菌の増殖性に対するボタンボウフウの影響を調べた。
なお、乳酸菌として、ラクトバシラス・ガセリ(Lactobacillus gasseri)と、ラクトバシラス・パラカゼイ(Lactobacillus paracasei)を用いた。より具体的には、ラクトバシラス・ガセリとしては、「NITE BP-01669」という寄託番号で独立行政法人製品評価技術基盤機構特許微生物寄託センターに寄託されており、商業的に入手することができる菌を、ラクトバシラス・パラカゼイとしては、「NITE BP-01633」という寄託番号で独立行政法人製品評価技術基盤機構特許微生物寄託センターに寄託されており、商業的に入手することができる菌を、それぞれ用いた。
<Experimental example 2>
In Experimental Example 2, the effect of button swell on the growth of lactic acid bacteria was examined.
In addition, Lactobacillus gasseri (Lactobacillus gasseri) and Lactobacillus paracasei (Lactobacillus paracasei) were used as lactic acid bacteria. More specifically, as Lactobacillus gasseri, a strain that has been deposited with the Patent Microorganism Depositary, National Institute of Technology and Evaluation, under the deposit number “NITE BP-01669”, can be obtained commercially. As the Lactobacillus paracasei, bacteria that have been deposited at the Patent Microorganism Depositary, National Institute for Product Evaluation and Technology under the deposit number “NITE BP-01633”, and are commercially available were used.
(1)各実験材料の調製
(1−1)乳酸菌の調製
乳酸菌を、蛋白質、アミノ酸、糖源を含有する培地に接種し、32〜41℃で5〜24時間培養を行った後、培養液から遠心分離により菌体(湿菌体)を集菌した。凍結乾燥機(共和真空社製)を用いて18〜96時間の凍結乾燥を行い、凍結乾燥終了後の菌体塊を物理的に粉砕して乳酸菌を得た。
(1) Preparation of each experimental material (1-1) Preparation of lactic acid bacteria Lactic acid bacteria are inoculated into a medium containing protein, amino acid, and sugar source, and cultured at 32 to 41 ° C for 5 to 24 hours. The cells (wet cells) were collected by centrifugation. Freeze-drying was performed for 18 to 96 hours using a freeze-dryer (manufactured by Kyowa Vacuum Co., Ltd.), and the cell mass after completion of freeze-drying was physically pulverized to obtain lactic acid bacteria.
(1−2)ボタンボウフウ溶液の調製
ボタンボウフウ粉末3gを水道水又は牛乳100mLに溶解してボタンボウフウ溶液を調製し、90℃で10分間オートクレーブ殺菌を行い、滅菌した。
(1-2) Preparation of button fountain solution 3 g of button fountain powder was dissolved in 100 mL of tap water or milk to prepare a button fountain solution, which was sterilized by autoclaving at 90 ° C. for 10 minutes.
(2)実験方法
試験管に入れた10mL量の各ボタンボウフウ溶液(滅菌済)に、10mLあたりの菌数が1.0×109cfu(1.0×108cfu/mL)となるように生理食塩水で希釈調整した乳酸菌を接種し、37℃で8時間培養した。培養後、培養物中の生菌数(cfu/mL)とpHを測定し、培養前の生菌数とpHと比較し、乳酸菌の増殖性及び生残性(生残率)に対するボタンボウフウの影響を評価した。なお、比較のため、上記ボタンボウフウ溶液に代えて、水道水又は牛乳を用いて、同様に実験を行った。
(2) Experimental method The number of bacteria per 10 mL becomes 1.0 × 10 9 cfu (1.0 × 10 8 cfu / mL) in each 10 mL amount of each button bow solution (sterilized) put in a test tube. Was inoculated with lactic acid bacteria diluted with physiological saline and cultured at 37 ° C. for 8 hours. After culturing, the number of viable bacteria in the culture (cfu / mL) and pH are measured, compared with the number of viable bacteria and pH before culturing, and the growth rate of lactic acid bacteria and the survival rate (survival rate). The impact was evaluated. For comparison, the same experiment was performed using tap water or milk instead of the button-bowl solution.
(3)実験結果
実施例3〜6および比較例3〜6の結果を表2に示す。
(3) Experimental results Table 2 shows the results of Examples 3 to 6 and Comparative Examples 3 to 6.
実施例3と比較例3との対比及び実施例4と比較例4との対比からわかるように、乳酸菌についても、前記実験例1と同様に、ボタンボウフウの存在下で培養することで、菌増殖が促進されて生残性が顕著に上昇することが判明した。
また、比較例4及び6に示すように、牛乳には乳酸菌の生残性を上昇させる効果があるものの、実施例4及び6に示すように、牛乳にボタンボウフウを組み合わせることで、ビフィズス菌の菌増殖がさらに一層促進されて、生菌数が顕著に増加することが判明した。
As can be seen from the comparison between Example 3 and Comparative Example 3 and the comparison between Example 4 and Comparative Example 4, lactic acid bacteria can also be cultured by culturing in the presence of button fountain, as in Experimental Example 1. It was found that the growth was promoted and the survival was significantly increased.
In addition, as shown in Comparative Examples 4 and 6, although milk has an effect of increasing the survival of lactic acid bacteria, as shown in Examples 4 and 6, by combining button fountain with milk, bifidobacteria It was found that the growth of the bacteria was further promoted and the number of viable bacteria was significantly increased.
<実験例3>
実験例3では、ビフィズス菌の増殖性に対するボタンボウフウとタンパク質および/または糖質との併用の影響を調べた。
なお、ビフィズス菌として、ビフィドバクテリウム・ロンガム(Bifidobacterium longum)を用いた。
<Experimental example 3>
In Experimental Example 3, the effect of combined use of button pea and protein and / or carbohydrate on the growth of Bifidobacteria was examined.
In addition, Bifidobacterium longum (Bifidobacterium longum) was used as a Bifidobacterium.
(1)各実験材料の調製
(1−1)ビフィズス菌の調製
実験例1と同様の方法により、ビフィズス菌を調整した。
(1) Preparation of each experimental material (1-1) Preparation of bifidobacteria Bifidobacteria were prepared in the same manner as in experimental example 1.
(1−2)ボタンボウフウ溶液の調製
[実施例7および8]
ボタンボウフウ粉末3gおよびタンパク質(カゼイン又はホエイタンパク質)を水道水100mLに溶解し、タンパク質濃度3質量%のボタンボウフウ溶液を調製した。このボタンボウフウ溶液を、90℃で10分間オートクレーブ殺菌を行い、滅菌した。
(1-2) Preparation of button-up solution [Examples 7 and 8]
3 g of button bow powder and protein (casein or whey protein) were dissolved in 100 mL of tap water to prepare a button bow solution having a protein concentration of 3% by mass. This button-bowl solution was sterilized by autoclaving at 90 ° C. for 10 minutes.
[実施例9]
ボタンボウフウ粉末3gおよび糖(ラクトース)を水道水100mLに溶解し、糖濃度5質量%のボタンボウフウ溶液を調製した。このボタンボウフウ溶液を、90℃で10分間オートクレーブ殺菌を行い、滅菌した。
[Example 9]
3 g of button bow powder and sugar (lactose) were dissolved in 100 mL of tap water to prepare a button bow solution having a sugar concentration of 5% by mass. This button-bowl solution was sterilized by autoclaving at 90 ° C. for 10 minutes.
(2)実験方法
試験管に入れた10mL量の各ボタンボウフウ溶液(滅菌済)に、10mLあたりの菌数が1.0×109cfu(1.0×108cfu/mL)となるように生理食塩水で希釈調整したビフィズス菌を接種し、37℃で8時間および16時間培養した。培養後、培養物中の生菌数(cfu/mL)とpHを測定し、培養前の生菌数とpHと比較し、ビフィズス菌の増殖性及び生残性(生残率)に対するボタンボウフウ、タンパク質及び糖質の影響を評価した。なお、比較のため、上記ボタンボウフウ溶液に代えて、タンパク質(カゼイン又はホエイタンパク質)をそれぞれ水道水に溶解したタンパク質濃度3質量%の水溶液(比較例7及び8)、糖(ラクトース)をそれぞれ水道水に溶解した糖濃度5質量%の水溶液(比較例9)を用いて、同様に実験を行った。
(2) Experimental method The number of bacteria per 10 mL becomes 1.0 × 10 9 cfu (1.0 × 10 8 cfu / mL) in each 10 mL amount of each button bow solution (sterilized) put in a test tube. Were inoculated with Bifidobacterium diluted with physiological saline and cultured at 37 ° C. for 8 hours and 16 hours. After culturing, the number of viable bacteria (cfu / mL) and pH in the culture are measured, and compared with the number of viable bacteria and pH before culturing, the button fountain for the growth and survival (survival rate) of bifidobacteria The effects of proteins and carbohydrates were evaluated. For comparison, instead of the above button-bowl solution, an aqueous solution (Comparative Examples 7 and 8) having a protein concentration of 3% by mass in which protein (casein or whey protein) is dissolved in tap water and sugar (lactose) are respectively supplied in tap water. Experiments were similarly performed using an aqueous solution (Comparative Example 9) having a sugar concentration of 5 mass% dissolved in water.
(3)実験結果
実施例7〜9および比較例7〜9の結果を表3に示す。
(3) Experimental results Table 3 shows the results of Examples 7 to 9 and Comparative Examples 7 to 9.
比較例7及び8に示す通り、ビフィズス菌を、タンパク質のみの存在下で培養すると、菌の生残性が低下するのに対して、実施例7及び8に示す通り、これらにボタンボウフウを組み合わせることで、ビフィズス菌の菌増殖が促進されて、生菌数が増加することが判明した。また、実施例9と比較例9との対比からわかるように、糖質についても、ボタンボウフウと組み合わせることで、ビフィズス菌の生残性が上昇することが分かった。 As shown in Comparative Examples 7 and 8, when bifidobacteria are cultured in the presence of protein alone, the viability of the bacteria is reduced, whereas as shown in Examples 7 and 8, button fountains are combined. Thus, it was found that the growth of bifidobacteria was promoted and the number of viable bacteria increased. In addition, as can be seen from the comparison between Example 9 and Comparative Example 9, it was found that the survival of bifidobacteria also increased with carbohydrates in combination with button bowfish.
<実験例4>
実験例4では、ビフィズス菌の増殖性・生残性に対するボタンボウフウ濃度の影響を調べた。
なお、ビフィズス菌として、ビフィドバクテリウム・ロンガム(Bifidobacterium longum)を用いた。
<Experimental example 4>
In Experimental Example 4, the effect of button swell concentration on the growth and survival of bifidobacteria was examined.
In addition, Bifidobacterium longum (Bifidobacterium longum) was used as a Bifidobacterium.
(1)各実験材料の調製
(1−1)ビフィズス菌の調製
実験例1と同様の方法により、ビフィズス菌を調整した。
(1) Preparation of each experimental material (1-1) Preparation of bifidobacteria Bifidobacteria were prepared in the same manner as in experimental example 1.
(1−2)ボタンボウフウ溶液の調製
ボタンボウフウ粉末を牛乳100mLに下記表4に示す濃度になるようにそれぞれ溶解し、各ボタンボウフウ溶液を調製した。このボタンボウフウ溶液を、90℃で10分間オートクレーブ殺菌を行い、滅菌した。
(1-2) Preparation of button fountain solution Each button fountain solution was prepared by dissolving button fountain powder in 100 mL of milk so as to have the concentrations shown in Table 4 below. This button-bowl solution was sterilized by autoclaving at 90 ° C. for 10 minutes.
(2)実験方法
試験管に入れた10mL量の各ボタンボウフウ溶液(滅菌済)に、10mLあたりの菌数が1.0×109cfu(1.0×108cfu/mL)となるように生理食塩水で希釈調整したビフィズス菌を接種し、37℃で8時間および16時間培養した。培養後、培養物中の生菌数(cfu/mL)とpHを測定し、培養前の生菌数とpHと比較し、ビフィズス菌の増殖性及び生残性(生残率)に対するボタンボウフウの濃度の影響を評価した。
(2) Experimental method The number of bacteria per 10 mL becomes 1.0 × 10 9 cfu (1.0 × 10 8 cfu / mL) in each 10 mL amount of each button bow solution (sterilized) put in a test tube. Were inoculated with Bifidobacterium diluted with physiological saline and cultured at 37 ° C. for 8 hours and 16 hours. After culturing, the number of viable bacteria (cfu / mL) and pH in the culture are measured, and compared with the number of viable bacteria and pH before culturing, the button fountain for the growth and survival (survival rate) of bifidobacteria The effect of concentration was evaluated.
(3)実験結果
実施例10〜14の結果を表4に示す。
(3) Experimental results Table 4 shows the results of Examples 10 to 14.
表4に示す通り、各実施例とも培養前のpHに対して8時間培養後のpHは低下する傾向が確認され、生菌数の減少が抑制されることが明らかとなった。このような生菌数の減少抑制効果は、ボタンボウフウの濃度依存的であることが明らかであり、ボタンボウフウが3質量%以上では、8時間後においても培養開始時の生菌数を維持していた。なお、ボタンボウフウ濃度が10質量%である実施例14では、その効果が生菌数の減少抑制から増殖促進の効果に転じ、ビフィズス菌を顕著に増殖促進することが判明した。 As shown in Table 4, in each Example, it was confirmed that the pH after culturing for 8 hours was lower than the pH before culturing, and the decrease in the number of viable bacteria was suppressed. It is apparent that the effect of suppressing the decrease in the number of viable bacteria is dependent on the concentration of button fountain. When the amount of button fountain is 3% by mass or more, the number of viable bacteria at the start of culture is maintained even after 8 hours. It was. In Example 14 where the concentration of button fountain was 10% by mass, it was found that the effect turned from the suppression of the decrease in the number of viable bacteria to the effect of promoting growth, and the growth of bifidobacteria was remarkably promoted.
<実験例5>
実験例5では、ビフィズス菌の増殖性及び生残性(生残率)に対する各種青汁製品の影響を調べた。
なお、ビフィズス菌として、ビフィドバクテリウム・ロンガム(Bifidobacterium longum)を用いた。
また、各種青汁製品として、以下の製品を用いた。
製品A/内容成分:大麦若葉、糖類、食物繊維など
製品B/内容成分:大麦若葉、海藻、デキストリン、クロレラなど
製品C/内容成分:糖類、デキストリン、大麦若葉、抹茶末など
製品D/内容成分:大麦若葉、糖類など
製品E/内容成分:大麦若葉
製品F/内容成分:大麦若葉、ケール、コラーゲン、デキストリン、糖類など
製品G/内容成分:クロレラ
<Experimental example 5>
In Experimental Example 5, the influence of various green juice products on the growth and survival (survival rate) of bifidobacteria was examined.
In addition, Bifidobacterium longum (Bifidobacterium longum) was used as a Bifidobacterium.
Moreover, the following products were used as various green juice products.
Product A / content ingredients: barley young leaves, sugar, dietary fiber, etc. Product B / content ingredients: barley young leaves, seaweed, dextrin, chlorella, etc. Product C / content ingredients: sugar, dextrin, barley young leaves, green tea powder, etc. Product D / content ingredients : Barley young leaves, sugars, etc. Product E / Content ingredients: Barley young leaves Product F / Content ingredients: Barley young leaves, kale, collagen, dextrin, sugars, etc. Product G / Content ingredients: Chlorella
(1)各実験材料の調製
(1−1)ビフィズス菌末の調製
実験例1と同様の方法により、ビフィズス菌末を調整した。
(1) Preparation of each experimental material (1-1) Preparation of bifidobacteria powder Bifidobacteria powder was prepared in the same manner as in Experimental Example 1.
(1−2)青汁の調製
各種青汁製品3gを水道水100mLに溶解して各種青汁を調製し、90℃で10分間オートクレーブ殺菌を行い、滅菌した。
(1-2) Preparation of green juice Various green juice products were prepared by dissolving 3 g of various green juice products in 100 mL of tap water, and sterilized by autoclaving at 90 ° C. for 10 minutes.
(2)実験方法
試験管に入れた10mL量の各種青汁(滅菌済)に、10mLあたりの菌数が1.0×109cfu(1.0×108cfu/mL)となるように生理食塩水で希釈調整したビフィズス菌を接種し、37℃で8時間培養した。培養後、培養物中の生菌数(cfu/mL)とpHを測定し、培養前の生菌数とpHと比較し、ビフィズス菌の増殖性に対する各種青汁製品の影響を評価した。なお、比較対照のため、上記各種青汁に代えて、水道水を用いて、同様に実験を行った。
(2) Experimental method The number of bacteria per 10 mL is 1.0 × 10 9 cfu (1.0 × 10 8 cfu / mL) in various types of green juice (sterilized) in 10 mL. Bifidobacteria diluted with physiological saline was inoculated and cultured at 37 ° C. for 8 hours. After culturing, the viable cell count (cfu / mL) and pH in the culture were measured, and compared with the viable cell count and pH before culturing, the influence of various green juice products on the growth of bifidobacteria was evaluated. In addition, it replaced with said various green juices for the comparison, and it experimented similarly using a tap water.
(3)実験結果
比較例A〜Gの結果を表5に示す。なお、参考のために実施例1の結果を併記した。
(3) Experimental results Table 5 shows the results of Comparative Examples A to G. For reference, the results of Example 1 are also shown.
表5に示す通り、ボタンボウフウを含む実施例1に比して、各種青汁製品では、ビフィズス菌の増殖促進効果が大きく異なることが分かった。また、ほとんどの青汁製品において、ビフィズス菌の生菌数の減少が確認され、生残性が実施例1に比して低下する結果が確認された。このような結果から、青汁製品の中でも、ボタンボウフウを含む本発明が顕著にビフィズス菌の生残率を向上させる効果を発揮することが明らかとなった。 As shown in Table 5, it was found that the growth promotion effect of bifidobacteria was greatly different in various green juice products as compared with Example 1 containing button bow fu. Moreover, in most of the green juice products, a decrease in the viable count of bifidobacteria was confirmed, and the result that the survivability decreased as compared with Example 1 was confirmed. From such a result, it became clear that among green juice products, the present invention including button swell exhibits the effect of significantly improving the survival rate of bifidobacteria.
Claims (13)
ビフィドバクテリウム属細菌および乳酸菌からなる群から選択される少なくとも1種の細菌と、を含む経口組成物。 Button bow,
An oral composition comprising at least one bacterium selected from the group consisting of Bifidobacterium and lactic acid bacteria.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015255967A JP6847577B2 (en) | 2015-12-28 | 2015-12-28 | Bifidobacterium and / or lactic acid bacteria growth promoter and / or reduction inhibitor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015255967A JP6847577B2 (en) | 2015-12-28 | 2015-12-28 | Bifidobacterium and / or lactic acid bacteria growth promoter and / or reduction inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017119633A true JP2017119633A (en) | 2017-07-06 |
JP6847577B2 JP6847577B2 (en) | 2021-03-24 |
Family
ID=59271432
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015255967A Active JP6847577B2 (en) | 2015-12-28 | 2015-12-28 | Bifidobacterium and / or lactic acid bacteria growth promoter and / or reduction inhibitor |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6847577B2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020054253A (en) * | 2018-09-28 | 2020-04-09 | 株式会社東洋新薬 | Oral composition |
CN114381390A (en) * | 2021-12-20 | 2022-04-22 | 美益添生物医药(武汉)有限公司 | Bifidobacterium longum ME-875 and application thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001224330A (en) * | 2000-02-17 | 2001-08-21 | Hideko Uechi | Food comprising lactobacillus symbiotic culture product and medicinal plant and method for producing the same |
WO2009054504A1 (en) * | 2007-10-24 | 2009-04-30 | Suntory Holdings Limited | Ligand agent for peroxisome proliferator-activated receptor (ppar) |
CN101422194A (en) * | 2008-10-31 | 2009-05-06 | 上海双金生物科技有限公司 | Yoghourt powder |
JP2013506631A (en) * | 2009-09-30 | 2013-02-28 | ネステク ソシエテ アノニム | Bifidobacterium longum ATCCBAA-999 (BL999) and weight control |
CN104531549A (en) * | 2014-05-28 | 2015-04-22 | 西南大学 | Lactobacillus fermentum zhao capable of regulating intestinal movement and preventing constipation |
JP2017055665A (en) * | 2015-09-14 | 2017-03-23 | 有限会社イントロン | Method for producing useful product |
-
2015
- 2015-12-28 JP JP2015255967A patent/JP6847577B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001224330A (en) * | 2000-02-17 | 2001-08-21 | Hideko Uechi | Food comprising lactobacillus symbiotic culture product and medicinal plant and method for producing the same |
WO2009054504A1 (en) * | 2007-10-24 | 2009-04-30 | Suntory Holdings Limited | Ligand agent for peroxisome proliferator-activated receptor (ppar) |
CN101422194A (en) * | 2008-10-31 | 2009-05-06 | 上海双金生物科技有限公司 | Yoghourt powder |
JP2013506631A (en) * | 2009-09-30 | 2013-02-28 | ネステク ソシエテ アノニム | Bifidobacterium longum ATCCBAA-999 (BL999) and weight control |
CN104531549A (en) * | 2014-05-28 | 2015-04-22 | 西南大学 | Lactobacillus fermentum zhao capable of regulating intestinal movement and preventing constipation |
JP2017055665A (en) * | 2015-09-14 | 2017-03-23 | 有限会社イントロン | Method for producing useful product |
Non-Patent Citations (1)
Title |
---|
PYTOTHERAPY RESEARCH, vol. 25, JPN6019024581, 2011, pages 870 - 877, ISSN: 0004388133 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020054253A (en) * | 2018-09-28 | 2020-04-09 | 株式会社東洋新薬 | Oral composition |
CN114381390A (en) * | 2021-12-20 | 2022-04-22 | 美益添生物医药(武汉)有限公司 | Bifidobacterium longum ME-875 and application thereof |
CN114381390B (en) * | 2021-12-20 | 2023-11-17 | 美益添生物医药(武汉)有限公司 | Bifidobacterium longum ME-875 and application thereof |
Also Published As
Publication number | Publication date |
---|---|
JP6847577B2 (en) | 2021-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7280243B2 (en) | Nutritional composition, food and drink composition and prepared milk powder using the nutritional composition | |
WO2020246585A1 (en) | Nutritional composition | |
JP6551934B2 (en) | Bifidobacterium and / or lactic acid bacteria growth promoter and / or suppressor | |
WO2021149663A1 (en) | Composition | |
JP2017109976A5 (en) | ||
WO2020246583A1 (en) | Composition | |
WO2019182160A1 (en) | Composition for enhancing breast milk component | |
JP6847577B2 (en) | Bifidobacterium and / or lactic acid bacteria growth promoter and / or reduction inhibitor | |
JP7368484B2 (en) | Composition, food and beverage compositions containing the composition, and formula milk | |
WO2019188943A1 (en) | Composition for preventing and/or ameliorating decrease in brain blood flow | |
AU2018414925B2 (en) | Composition for promoting the secretion of FGF21 | |
WO2020116511A1 (en) | Composition for suppressing norovirus infection | |
JPWO2019180965A1 (en) | Infant composition for the prevention of diseases caused by hyperglycemia after school age | |
Kumar et al. | Composite Probiotic Dairy Products: Concepts and Design with a Focus on Millets | |
JP2021121584A (en) | Motor function-improving composition and activity-promoting composition | |
JP2021182889A (en) | Composition for improving pulmonary functions, and composition for preventing, treating or alleviating pulmonary diseases | |
JP2021023181A (en) | Composition for promoting proliferation of specific bifidobacterium bacteria in human intestinal tract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180925 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190702 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190830 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191031 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200107 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200302 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200430 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200901 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201027 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201117 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210105 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210224 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210303 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6847577 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |